Overview

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

This study is a single-arm Phase II trial designed to evaluate the efficacy and safety of Docetaxel, Nimotuzumab, and Pucotenlimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed prior PD-1/PD-L1 inhibitor and platinum-based therapies, for second-line and later-line treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

Biotech Pharmaceutical Co., Ltd.
Lepu Biopharma Co., Ltd.

Treatments:

Docetaxel
Drug Therapy, Combination
nimotuzumab